Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
$0.99
$0.99
$0.99
▼
$0.99
N/A0.25N/AN/A
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
$2.08
-3.7%		$4.04
$3.36
▼
$26.30
$19.40M1.51628,703 shs126,966 shs
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
$20.00
$20.00
$9.10
▼
$20.00
$357M0.53600 shsN/A
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
0.00%0.00%0.00%0.00%0.00%
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
0.00%0.00%0.00%0.00%+7.77%
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
0.00%0.00%0.00%0.00%+113.68%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
$0.99
$0.99
$0.99
▼
$0.99
N/A0.25N/AN/A
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
$2.08
-3.7%		$4.04
$3.36
▼
$26.30
$19.40M1.51628,703 shs126,966 shs
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
$20.00
$20.00
$9.10
▼
$20.00
$357M0.53600 shsN/A
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
0.00%0.00%0.00%0.00%0.00%
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
0.00%0.00%0.00%0.00%+7.77%
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
0.00%0.00%0.00%0.00%+113.68%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
0.00
N/AN/AN/A
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
0.00
N/AN/AN/A
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
N/AN/AN/AN/AN/AN/A
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
N/AN/AN/AN/A($0.76) per shareN/A
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
$6.82M52.35N/AN/A$0.21 per share95.24
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/AN/A
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
-$32.67M-$11.50N/AN/AN/AN/A-482.96%-258.47%N/A
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
-$17.63MN/AN/AN/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
N/AN/AN/AN/AN/A
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
N/AN/AN/AN/AN/A
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
N/AN/AN/A
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
N/A
1.33
1.33
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
N/A
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
6.27%
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
N/A
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
7.30%
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
26N/AN/ANot Optionable
AzurRx BioPharma, Inc. stock logo
AZRX
AzurRx BioPharma
129.33 million8.65 millionNot Optionable
Newron Pharmaceuticals S.p.A. stock logo
NWPHF
Newron Pharmaceuticals
2217.85 millionN/ANot Optionable

Recent News About These Companies

Die Newron Pharmaceuticals-Aktie gibt nach: Im Forum wachsen die Zweifel
August 2, 2026  |  wallstreet-online.deW
Newron Pharmaceuticals provides update following Type A meeting with the US FDA
July 4, 2026  |  pharmabiz.comP
Newron charts course forward for stalled schizophrenia drug
July 3, 2026  |  pharmaphorum.comP
Newron Pharmaceuticals to Participate in June Investor Conferences
May 28, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260528000168/en/newron-pharmaceuticals-to-participate-in-june-investor-conferences/
Newron announces US FDA has placed a hold on enrollment of new patients in US sites of its ENIGMA-TRS 2 study of evenamide
May 2, 2026  |  pharmabiz.comP
Patient death prompts FDA pause on Newron’s Phase 3 schizophrenia study
April 30, 2026  |  biospace.comB
Patient death puts Newron’s late-stage schizophrenia trial on ice
April 30, 2026  |  yahoo.comhttps://www.yahoo.com/news/articles/patient-death-puts-newron-stage-121132757.html
Newron Reports a Pause of Enrollment of New Study Participants in US Centers of ENIGMA-TRS 2 Study
April 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/newron-reports-pause-enrollment-study-155000195.html
FDA hits Newron’s phase 3 schizophrenia trial with clinical hold in US after patient death
April 29, 2026  |  fiercebiotech.comF
Newron Announces AGM 2026 Results
April 23, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/newron-announces-agm-2026-results-212445547.html
Newron Pharmaceuticals S.p.A. (VTX:NWRN) Analysts Just Slashed This Year's Estimates
March 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/newron-pharmaceuticals-p-vtx-nwrn-064621118.html
Newron Pharmaceuticals S.p.A. (VTX:NWRN) Analysts Are Cutting Their Estimates: Here's What You Need To Know
March 27, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/newron-pharmaceuticals-p-vtx-nwrn-045233774.html
Newron Pharmaceuticals S.p.A. (NWPHF) Q4 2025 Earnings Call Transcript
March 24, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4885570-newron-pharmaceuticals-s-p-a-nwphf-q4-2025-earnings-call-transcript
EQS-News: Newron presents 2025 financial results and provides 2026 outlook
March 24, 2026  |  sharewise.comS
Newron Presents 2025 Financial Results and Provides 2026 Outlook
March 24, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/newron-presents-2025-financial-results-110000063.html
Newron to Present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
March 20, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260320454898/en/Newron-to-Present-at-the-2026-Annual-Congress-of-the-Schizophrenia-International-Research-Society-SIRS/
Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 Finance Contract
March 19, 2026  |  pharmiweb.comP
Newron Announces Nominations to Its Board of Directors at Upcoming Annual General Meeting
March 18, 2026  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2026/03/18/10350202.htm
Newron Secures Funding to Advance Key Schizophrenia Drug
March 17, 2026  |  newscase.comN
Newron secures up to EUR 38 million to advance its ENIGMA-TRS pivotal phase III programme
February 18, 2026  |  pharmabiz.comP
Addex Therapeutics stock logo

Addex Therapeutics OTCMKTS:ADDXF

$0.99 0.00 (0.00%)
As of 02/3/2023

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot-Marie-Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

AzurRx BioPharma stock logo

AzurRx BioPharma NASDAQ:AZRX

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.

Newron Pharmaceuticals stock logo

Newron Pharmaceuticals OTCMKTS:NWPHF

$20.00 0.00 (0.00%)
As of 08/21/2026

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas